|
1.
|
Ferlay J, Shin HR, Bray F, et al:
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int
J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jemal A, Bray F, Center MM, et al: Global
Cancer Statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
3.
|
Henderson IC, Berry DA, Demetri GD, et al:
Improved outcomes from adding sequential Paclitaxel but not from
escalating Doxorubicin dose in an adjuvant chemotherapy regimen for
patients with node-positive primary breast cancer. J Clin Oncol.
21:976–983. 2003. View Article : Google Scholar
|
|
4.
|
Hortobagyi GN: Treatment of breast cancer.
N Engl J Med. 339:974–984. 1998. View Article : Google Scholar
|
|
5.
|
Dean-Colomb W and Esteva FJ: Emerging
agents in the treatment of anthracycline- and taxane-refractory
metastatic breast cancer. Semin Oncol. 35:S31–S38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Overmoyer B: Options for the treatment of
patients with taxane-refractory metastatic breast cancer. Clin
Breast Cancer. 8:S61–S70. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Llombart-Cussac A, Theodoulou M, Rowland
K, et al: Pemetrexed in patients with locally advanced or
metastatic breast cancer who had received previous anthracycline
and taxane treatment: phase II study. Clin Breast Cancer.
7:380–385. 2006. View Article : Google Scholar
|
|
8.
|
Martin M, Spielmann M, Namer M, et al:
Phase II study of pemetrexed in breast cancer patients pretreated
with anthracyclines. Ann Oncol. 14:1246–1252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Miles DW, Smith IE, Coleman RE, et al: A
phase II study of pemetrexed disodium (LY231514) in patients with
locally recurrent or metastatic breast cancer. Eur J Cancer.
37:1366–1371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Crown J and Pegram M: Platinum-taxane
combinations in metastatic breast cancer: an evolving role in the
era of molecularly targeted therapy. Breast Cancer Res Treat.
79:S11–S18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Martín M: Platinum compounds in the
treatment of advanced breast cancer. Clin Breast Cancer. 2:190–208.
2001.PubMed/NCBI
|
|
12.
|
Perez EA, Hillman DW, Stella PJ, et al: A
phase II study of paclitaxel plus carboplatin as first-line
chemotherapy for women with metastatic breast carcinoma. Cancer.
88:124–131. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Garin A, Manikhas A, Biakhov M, et al: A
phase II study of pemetrexed and carboplatin in patients with
locally advanced or metastatic breast cancer. Breast Cancer Res
Treat. 110:309–315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Heinemann V, Stemmler HJ, Wohlrab A, et
al: High efficacy of gemcitabine and cisplatin in patients with
predominantly anthracycline- and taxane-pretreated metastatic
breast cancer. Cancer Chemother Pharmacol. 57:640–646. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Perez EA: Carboplatin in combination
therapy for metastatic breast cancer. Oncologist. 9:518–527. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Brodowicz T, Kostler WJ, Möslinger R, et
al: Single-agent gemcitabine as second- and third-line treatment in
metastatic breast cancer. Breast. 9:338–342. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Spielmann M, Llombart-Cussac A, Kalla S,
et al: Single-agent gemcitabine is active in previously treated
metastatic breast cancer. Oncology. 60:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Blackstein M, Vogel CL, Ambinder R, et al:
Gemcitabine as first-line therapy in patients with metastatic
breast cancer: a phase II trial. Oncology. 62:2–8. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Heinemann V: Role of gemcitabine in the
treatment of advanced and metastatic breast cancer. Oncology.
64:191–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Heinemann V: Gemcitabine in metastatic
breast cancer. Expert Rev Anticancer Ther. 5:429–443. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Modi S, Currie VE, Seidman AD, et al: A
phase II trial of gemcitabine in patients with metastatic breast
cancer previously treated with an anthracycline and taxane. Clin
Breast Cancer. 6:55–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Albain KS, Nag SM, Calderillo-Ruiz G, et
al: Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in
patients with meta-static breast cancer and prior anthracycline
treatment. J Clin Oncol. 26:3950–3957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Seo JH, Oh SC, Choi CW, et al: Phase II
study of a gemcitabine and cisplatin combination regimen in taxane
resistant meta-static breast cancer. Cancer Chemother Pharmacol.
59:269–274. 2007.PubMed/NCBI
|
|
24.
|
Silvestris N, D’Aprile M, Andreola G, et
al: Rationale for the use of gemcitabine in breast cancer (Review).
Int J Oncol. 24:389–398. 2004.PubMed/NCBI
|
|
25.
|
Jones S, Winer E, Vogel C, et al:
Randomized comparison of vinorelbine and melphalan in
anthracycline-refractory advanced breast cancer. J Clin Oncol.
13:2567–2574. 1995.PubMed/NCBI
|
|
26.
|
Martín M, Ruiz A, Muñoz M, et al:
Gemcitabine plus vinorelbine monotherapy in patients with
metastatic breast cancer previously treated with anthracyclines and
taxanes: final results of the phase III Spanish Breast Cancer
Research Group (GEICAM) trial. Lancet Oncol. 8:219–225. 2007.
|
|
27.
|
Pallis AG, Boukovinas I, Ardavanis A, et
al: A multicenter randomized phase III trial of
vinorelbine/gemcitabine doublet versus capecitabine monotherapy in
anthracycline- and taxanepretreated women with metastatic breast
cancer. Ann Oncol. 23:1164–1169. 2012. View Article : Google Scholar
|
|
28.
|
Degardin M, Bonneterre J, Hecquet B, et
al: Vinorelbine (navelbine) as a salvage treatment for advanced
breast cancer. Ann Oncol. 5:423–426. 1994.PubMed/NCBI
|
|
29.
|
Gregory RK and Smith IE: Vinorelbine - a
clinical review. Br J Cancer. 82:1907–1913. 2000.PubMed/NCBI
|
|
30.
|
Haider K, Kornek GV, Kwasny W, et al:
Treatment of advanced breast cancer with gemcitabine and
vinorelbine plus human granulocyte colony-stimulating factor.
Breast Cancer Res Treat. 55:203–211. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Valenza R, Leonardi V, Gebbia V, et al:
Gemcitabine and vinorelbine in pretreated advanced breast cancer: a
pilot study. Ann Oncol. 11:495–496. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Stathopoulos GP, Rigatos SK, Pergantas N,
et al: Phase II trial of biweekly administration of vinorelbine and
gemcitabine in pretreated advanced breast cancer. J Clin Oncol.
20:37–41. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Stemmler HJ, diGioia D, Freier W, Tessen,
et al: Randomised phase II trial of gemcitabine plus vinorelbine vs
gemcitabine plus cisplatin vs gemcitabine plus capecitabine in
patients with pretreated metastatic breast cancer. Br J Cancer.
104:1071–1078. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
35.
|
Hughes A, Calvert P, Azzabi A, et al:
Phase I clinical and pharmacokinetic Study of pemetrexed and
carboplatin in patients with malignant pleural mesothelioma. J Clin
Oncol. 20:3533–3544. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Cancer Therapy Evaluation Program: Common
Terminology Criteria for Adverse Events, Version 3.0, 2003.
National Cancer Institute. Available, Published online August 9,
2006; available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcev3.pdf.
Accessed November 14, 2011.
|
|
37.
|
Nagel GC, Schmidt S, Strauss BM, et al:
Quality of life in breast cancer patients: a cluster analytic
approach. Empirically derived subgroups of the EORTC-QLQ BR 23 - a
clinically oriented assessment. Breast Cancer Res Treat. 68:75–87.
2001. View Article : Google Scholar
|
|
38.
|
Simon R: Optimal two-stage designs for
phase II clinical trials. Control Clin Trials. 10:1–10. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Clopper CJ and Pearson ES: The use of
confidence or fiducial limits illustrated in the case of the
binomial. Biometrika. 26:404–413. 1934. View Article : Google Scholar
|
|
40.
|
Kaplan EL and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
41.
|
Brookmeyer R and Crowley J: A confidence
interval for the median survival time. Biometrics. 38:29–41. 1982.
View Article : Google Scholar
|
|
42.
|
Nicolaides C, Dimopoulos MA, Samantas E,
et al: Gemcitabine and vinorelbine as second-line treatment in
patients with meta-static breast cancer progressing after
first-line taxane-based chemotherapy: a phase II study conducted by
the Hellenic Cooperative Oncology Group. Ann Oncol. 11:873–875.
2000. View Article : Google Scholar
|
|
43.
|
Park IH, Ro J, Lee KS, et al: Phase II
study of gemcitabine in combination with vinorelbine versus
gemcitabine followed by vinorelbine for metastatic breast cancer.
Invest New Drugs. 28:659–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Shehata S, Saad E, Goda Y, et al: A phase
II study of gemcitabine combined with vinorelbine as first-line
chemotherapy for metastatic breast cancer. Hematol Oncol Stem Cell
Ther. 3:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Morabito A, Filippelli G, Palmeri S, et
al: The combination of gemcitabine and vinorelbine is an active
regimen as second-line therapy in patients with metastatic breast
cancer pretreated with taxanes and/or anthracyclines: a phase I–II
study. Breast Cancer Res Treat. 78:29–36. 2003.
|
